Table 1.
Detailed clinicopathological findings and prognosis in four patients with MTX-associated PHL.
| Year | Author | Sex | Treatment | Diagnosis | Pathology | Number of tumors | Immunohistochemistry | Prognosis |
|---|---|---|---|---|---|---|---|---|
| 2015 | K. Miyagawa | F | R-CHOP | US-guided aspiration biopsy |
DLBCL | Multiple | CD10+, CD79a+, CD20+ CD5-, EBER- |
Alive |
| 2014 | G. Tatsumi | F | R-THP-COP | US-guided fine-needle biopsy | DLBCL | Multiple | CD10-, CD20+, CD5- EBER+ |
Alive |
| 2015 | A. Kawahara | M | R-CHOP | Percutaneous tumor biopsy |
DLBCL | Multiple | CD10+, CD79a+, CD20+ bcl-2-, CD3-, EBER- |
Alive |
| 2016 | Our case | F | MTX withdrawal | Surgery | DLBCL | Single | CD10-, CD15-, CD20+ CD30+, CD79a+, EBER+ |
Alive |
Abbreviations: bcl, B cell lymphoma; DLBCL, diffuse large B cell lymphoma; EBER, EBV-encoded small RNA; F, female; M, male; R-CHOP, rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone.